This information is essential for elucidating cellular susceptibility to apoptosis and for informing the application of targeted therapies such as Bcl-2 inhibitors (e.g., venetoclax), which are designed to induce apoptosis in AML cells exhibiting high levels of apoptotic priming and dependence on the Bcl-2 protein [45]. This evidence concerns the gene BCL2 and acute myeloid leukemia.